Exploratory analysis links abacavir use to increased cardiovascular risk in HIV patients. Study findings will be presented at the 2024 International AIDS Conference.
- Analysis of a large international clinical trial showed that the antiretroviral drug abacavir was associated with an increased risk of major adverse cardiovascular events (MACE) in people with HIV.
- The REPRIEVE study enrolled 7,769 HIV-positive participants from 12 countries and found that daily statin use reduced the risk of cardiovascular events, but certain antiretroviral drugs, including abacavir, were linked to MACE risk.
- Participants with prior or current exposure to abacavir had a significantly higher risk of MACE compared to those who had not taken the drug, while other antiretroviral drugs did not show this association.
- The findings highlight the need for further research to understand the increased cardiovascular risk associated with abacavir, especially in the context of other risk factors like dyslipidemia, diabetes, and hypertension in people with HIV.
- The study results will be presented at the 2024 International AIDS Conference in Munich, Germany.
Source link
Infectious Diseases, HIV/AIDS, Cardiology